FDA Policy for REMS Reqmts during COVID-19
Health Care, Pharma Industry, Strategic Planning
FDA is issuing this guidance to communicate its temporary policy for certain risk evaluation and mitigation strategies (REMS) requirements for the duration of the coronavirus pandemic public health emergency.
Read the Policy now
Related Education Resources.
All ResourcesFDA Guidance on CT Mgmt during COVID-19
Topics: Health Care, Pharma Industry, Strategic Planning
Guidance Document
Free
Overview of DtP Models for Clinical Trials
Topic: Conference
Video
Members
Leadership Lessons for Re-Entry
Topics: Leadership, Management
Webinar
Free
